Related Experiment Videos
Trimodality therapy for non-small-cell lung cancer
1Department of Cardiac and Thoracic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Oncology (Williston Park, N.Y.)
|November 7, 1999
Summary
Multimodality treatment, including neoadjuvant chemoradiotherapy for non-small-cell lung cancer, significantly improves 5-year survival rates in patients with locally advanced disease. This approach is also key for unresectable stage III non-small-cell lung cancer.
Area of Science:
- Oncology
- Thoracic Surgery
- Radiation Oncology
Background:
- Multimodality treatment has shown significant promise for non-small-cell lung cancer (NSCLC).
- Neoadjuvant chemoradiotherapy followed by surgery has demonstrated dramatic 5-year survival results in phase III trials for locally advanced, resectable NSCLC.
- Chemotherapy and radiation therapy combination is an established treatment for unresectable stage III NSCLC.
Purpose of the Study:
- To review the historical development of multimodality therapies for NSCLC.
- To compare neoadjuvant multimodality treatment with postoperative adjuvant therapy.
- To discuss the role of trimodality therapy in stage IIIB NSCLC and explore future directions.
Main Methods:
- Review of phase III clinical trials data.
- Historical analysis of treatment evolution.
- Comparative analysis of neoadjuvant versus adjuvant strategies.
Main Results:
- Neoadjuvant chemoradiotherapy followed by resection yields substantial improvements in 5-year survival for locally advanced NSCLC.
- Combined chemotherapy and radiation therapy is effective for unresectable stage III NSCLC.
- Trimodality therapy shows potential for stage IIIB disease.
Conclusions:
- Multimodality treatment, particularly neoadjuvant chemoradiotherapy, has substantially improved outcomes for advanced non-small-cell lung cancer.
- Further research into trimodality therapy and novel approaches is crucial for enhancing cure rates in advanced NSCLC.